Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

1.2K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

789
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
789
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

484
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
484
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

1.9K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Shaping the future of clinical trials through strategic foresight.

Clinical trials (London, England)·2026
Same author

Growth hormone causes reversible fibrosis in muscle and fat: a study in patients with acromegaly.

European journal of endocrinology·2026
Same author

Reduced Activity of Soluble Fibroblast Activation Protein (sFAP) Represents a Biomarker of Aggressive Disease in Lymphoid Malignancies.

International journal of molecular sciences·2025
Same author

GH replacement therapy in adults stimulates fibroblast activation protein-α activity.

European journal of endocrinology·2025
Same author

The pro-atherogenic enzyme PAPP-A is active in eluates from human carotid and femoral atherosclerotic plaques.

Atherosclerosis plus·2024
Same author

Inflammatory response after prehospital high-dose glucocorticoid to patients resuscitated from out-of-hospital cardiac arrest: A sub-study of the STEROHCA trial.

Resuscitation·2024

Related Experiment Video

Updated: Apr 19, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

6.0K

Osteoprotegerin levels change during STEMI and reflect cardiac function.

Søren Lindberg1, Jan S Jensen2, Søren Hoffmann1

  • 1Department of Cardiology P, Gentofte University Hospital, Copenhagen, Denmark.

The Canadian Journal of Cardiology
|December 6, 2014
PubMed
Summary

Osteoprotegerin (OPG) levels change during ST-elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI). Higher OPG levels are linked to reduced left ventricular ejection fraction (LVEF) after STEMI.

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.3K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.8K

Related Experiment Videos

Last Updated: Apr 19, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

6.0K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.3K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.8K

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Inflammation Research

Background:

  • Elevated osteoprotegerin (OPG) indicates poor prognosis in ST-elevation myocardial infarction (STEMI).
  • OPG may contribute to vascular inflammation and myocardial damage in STEMI.
  • The dynamic changes and clinical impact of OPG during STEMI treatment require further investigation.

Purpose of the Study:

  • To investigate the temporal changes in circulating osteoprotegerin (OPG) levels during ST-elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI).
  • To determine the association between OPG levels and cardiac function, specifically left ventricular ejection fraction (LVEF), following STEMI.

Main Methods:

  • Prospective study of 42 STEMI patients undergoing primary PCI.
  • Serial blood sampling (pre-PCI, post-PCI, day 1, day 2) for plasma OPG measurement using an in-house immunoassay.
  • Echocardiography to assess left ventricular ejection fraction (LVEF) 1-3 days post-STEMI.

Main Results:

  • OPG levels peaked post-PCI and subsequently decreased, showing a significant temporal change (P < 0.001).
  • OPG response preceded inflammatory markers like troponin I and C-reactive protein.
  • Patients with reduced LVEF (<40%) demonstrated a significantly higher OPG response throughout the STEMI treatment course (P = 0.009).

Conclusions:

  • Circulating OPG levels exhibit dynamic alterations during STEMI treated with primary PCI.
  • Elevated OPG levels are independently associated with impaired left ventricular ejection fraction (LVEF) in STEMI patients.